Nanoparticles creating a powerful anti-PD-L1 response inside tumors for advanced immune therapy

CAPRN demonstrates significant anti-tumor efficacy and substantial tumor suppression in both primary and bilateral tumor models.

• CAPRN is designed to enhance immune checkpoint blockade therapy by facilitating targeted antibody production and inducing cell death in tumors.
• The nanoparticle achieves tumor-specific accumulation by detaching in response to pH changes, allowing for effective delivery of genetic material encoding anti-PD-L1 antibodies.
• Laser-induced photodynamic therapy not only causes cancer cell death but also promotes the release of antibodies from dying tumor cells.
• Observations indicate enhanced antibody release, maturation of dendritic cells, and activation of T cells, contributing to improved anti-tumor responses.
• The approach is associated with increased infiltration of activated T cells and heightened immune responses within the tumor microenvironment.

Simplified